RecruitingPhase 1 / Phase 2NCT07531745
Neurological
Dravet Syndrome
Also known as Severe myoclonic epilepsy of infancy, SMEI, SCN1A epileptic encephalopathy
Dravet syndrome is a severe developmental and epileptic encephalopathy caused in approximately 80% of cases by de novo loss-of-function mutations in SCN1A, encoding the Nav1.
ORPHA:33069 ↗Gene SCN1APrevalence 1-9 per 100,000 (Orphanet)Onset InfantileAutosomal dominant genetic (de novo in most cases)
16
studies recruiting now
as of 7 Sept 2026
103
studies registered in total
as of 7 Sept 2026
23
countries with a recruiting site
as of 7 Sept 2026
15 Apr 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT06872125
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
RecruitingPhase 1 / Phase 2NCT05419492
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RecruitingPhase 3NCT04462770
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
RecruitingPhase 3NCT06660394
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 16 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Dravet Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: Dravet Syndrome Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Dravet Syndrome
Dravet syndrome is a severe developmental and epileptic encephalopathy caused in approximately 80% of cases by de novo loss-of-function mutations in SCN1A, encoding the Nav1.1 sodium channel subunit. Onset occurs in the first year of life with prolonged febrile and afebrile seizures, followed by developmental plateau and multiple seizure types that are refractory to conventional antiseizure medications. Sodium channel blockers (e.g., carbamazepine, phenytoin) worsen seizures and are contraindicated.
Common clinical features
Prolonged febrile seizuresMultiple seizure types (myoclonic, focal, absence)Developmental plateauAtaxiaSleep disturbanceHyperthermia-triggered seizuresBehavioral problems
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
3 approved treatments and 7 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Stiripentol (Diacomit)Approved: Cannabidiol (Epidiolex)Approved: Fenfluramine Hydrochloride (Fintepla)
Phase 3Zorevunersen
Phase 3Clobazam (Frisium)
Phase 3Fenfluramine
Phase 2Soticlestat
Phase 2Ataluren (Translarna)
Phase 2(S)-Verapamil
Phase 2Verapamil
Before you apply
Things trial teams commonly ask about for Dravet Syndrome. Not eligibility rules; those are set by each study.
- SCN1A variant classification (pathogenic, likely pathogenic) and functional impact are required for gene therapy trial eligibility
- Sodium channel blockers are contraindicated — ensure current antiseizure medication list is provided; trials screen for contraindicated drugs
- Seizure frequency diary (minimum 3 months) is a standard inclusion criterion — document baseline convulsive seizure count
- Fenfluramine (Fintepla) and cannabidiol (Epidiolex) are approved add-on therapies — prior treatment history affects trial stratification
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).